RPI has announced that four of their joint health formulae manufactured in tablet form have been approved for the USP DSVP (Dietary Supplement Verification Program) and RPI has earned the authorization to use the USP Verified Mark (DSVP) on the product labels. The USP Verification Program is a rigorous, in-depth program involving auditing, product testing, document review and continuing surveillance activities; and covers compliance with Federal cGMP regulations. Further information can be obtained on the USP Verified website (http://www.usp.org/USPVerified/).
USP has issued approval letters (DSVP Ref. No.: 1083100402,3,4,&5) confirming that the Robinson Pharma Inc. manufactured Glucosamine based joint health formulations that include Glucosamine HCL, Glucosamine HCL with MSM, Glucosamine with Chondroitin, & Glucosamine, Chondroitin, MSM, with Vitamin D products meet the requirements of the Dietary Supplement Verification Program (DSVP). USP conducted audits of Robinson Pharma Inc.’s facility and quality systems, including a review of staff training, manufacturing operations, supply chain qualification for all ingredients used in the manufacture of the products, and the stability studies for the products post manufacturing. The USP DSVP takes a comprehensive approach to product quality and it is the depth and breadth of the USP program that sets it apart from many other cGMP compliance programs that focus on strictly manufacturing practices. The announcement of USP DSVP compliance follows the recent news of verification of RPI Fish oil 30% EPA/DHA MEG-3 USP Softgels.
“Earning the USP DSVP mark for four of our most important tablet formulations demonstrates that RPI is deeply committed to its quality program and that our quality infrastructure extends beyond softgels to all aspects of our operation. We are very pleased that our team has replicated its earlier success with our Fish oil 30% EPA/DHA MEG-3 USP Softgels and has earned four verifications covering five high profile joint health products,” stated company founder, Tom Nguyen.
“Making products that meet the rigorous standards of USP DSVP demands a high level of control. We have demonstrated the ability to manage all aspects of the product process, from formulation and ingredient acquisition, through packaging. The USP DSVP standard addresses all factors that can impact product integrity and customer experience.” Fred Jamee, Senior Vice President of Quality and Compliance for Robinson Pharma added “The speed with which we achieved verification on the four additional formulations demonstrates that the systems we created to achieve our first USP DSVP product, Fish oil 30% EPA/DHA MEG-3 USP Softgels, have become well established throughout our operation.”
“Having flagship products that comply with USP DSVP distributed within our product range is a strong statement about the depth and breadth of our quality program. The certification of 5 tablet products, based on 4 ingredient formulations, is a strong indicator that our quality program is working well across and throughout our company. This most recent award of the USP Verified mark to our most important tablets products is a great opportunity to show our strength in our non-softgel business,” Stated Kenn Israel, Vice President of Marketing.
Robinson Pharma Inc. (RPI) is a minority owned, Southern California based full service provider of private label, store brand, and contract manufacturing services for dietary supplements and pharmaceuticals. RPI features the largest soft gel encapsulation capacity in the U.S. with 20 continuous dry encapsulation lines capable of producing over 12 billion soft gels per year. Additional production capabilities include tablet compression, hard shell capsule filling, enteric coating of soft gels and tablets, custom imprinting, and a range of packaging options including bottles, blister packaging, boxing, and bulk product. Services offered include product development and ingredient sourcing. Robinson Pharma Inc. provides rapid turnaround on all projects and offers highly competitive pricing. Robinson Pharma Inc. maintains 400,000 square feet of production, operations, and warehousing facilities. For more information please visit www.RobinsonPharma.com